The Effect of Hepatic Impairment on the Pharmacokinetics of RO5190591/Ritonavir: A Multiple-Center, Open-Label Study Following Multiple Oral Doses of RO5190591/Ritonavir to Subjects with Mild, Moderate, or Severe Hepatic Impairment and Healthy Subjects with Normal Hepatic Function

Trial Profile

The Effect of Hepatic Impairment on the Pharmacokinetics of RO5190591/Ritonavir: A Multiple-Center, Open-Label Study Following Multiple Oral Doses of RO5190591/Ritonavir to Subjects with Mild, Moderate, or Severe Hepatic Impairment and Healthy Subjects with Normal Hepatic Function

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Danoprevir (Primary) ; Ritonavir (Primary)
  • Indications Hepatitis C; HIV infections
  • Focus Pharmacokinetics
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 04 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 May 2013 Planned end date changed from 1 Jul 2012 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 07 May 2013 Status changed from completed to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top